Structural basis for selective inhibition of Src family kinases by PP1

Chemistry and Biology

Volumn 6, Issue 9, 1999, Pages 671-678

  Liu, Yi ^a   Bishop, Anthony ^a   Witucki, Laurie ^a   Kraybill, Brian ^a   Shimizu, Eiji ^a   Tsien, Joe ^a   Ubersax, Jeff ^b   Blethrow, Justin ^b   Morgan, David O ^b   Shokat, Kevan M ^a,b  

^a PRINCETON UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Kinase inhibitor; Modeling; PP1; Selective; Src

Indexed keywords

EID: 0033200390     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(99)80118-5     Document Type: Article

References (53)

1. Isakov, N., Wange, R.L. & Samelson, L.E. (1994). The role of tyrosine kinases and phosphotyrosine-containing recognition motifs in regulation of the T cell-antigen receptor-mediated signal transduction pathway. J. Leukoc. Biol. 55, 265-271.
2. Perlmutter, R.M. (1995). Control of T cell development by non-receptor protein tyrosine kinases. Cancer Surv. 22, 85-95.
3. Martin, K.C., et al., & Kandel, E.R. (1997). MAP kinase translocates into the nucleus of the presynaptic cell and is required for long-term facilitation in aplysia. Neuron 18, 899-912.
4. Holm, N.R., Christophersen, P., Olesen, S.P. & Gammeltoft, S. (1997). Activation of calcium-dependent potassium channels in mouse [correction of rat] brain neurons by neurotrophin-3 and nerve growth factor. Proc. Natl Acad. Sci. USA 94, 1002-1006.
5. Hunter, T. (1994). 1001 protein kinases redux-towards 2000. Semin. Cell Biol. 5, 367-376.
6. Shokat, K.M. (1995). Tyrosine kinases: Modular signaling enzymes with tunable specificities. Chem. Biol. 2, 509-514.
7. Thomas, S.M., Soriano, P. & Imamoto, A. (1995). Specific and redundant roles of Src and Fyn in organizing the cytoskeleton. Nature 376, 267-271.
8. Bolen, J.B., Rowley, R.B., Spana, C. & Tsygankov, A.Y. (1992). The Src family of tyrosine protein kinases in hemopoietic signal transduction. FASEB J. 6, 3403-3409.
9. Ilic, D., et al., & Aizawa, S. (1995). Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377, 539-544.
10. Bishop, A.C., Shah, K., Liu, Y., Witucki, L., Kung, C. & Shokat, K.M. (1998). Design of allele-specific inhibitors to probe protein kinase signaling. Curr. Biol. 8, 257-266.
11. Bishop, A.C., Kung, C., Shah, K., Witucki, L., Shokat, K.M. & Liu, Y. (1999). Generation of monospecific nanomolar tyrosine kinase inhibitors via a chemical genetic approach. J. Am. Chem. Soc. 121, 627-631.
12. Hunter, T. (1987). A thousand and one protein kinases. Cell 50, 823-829.
13. Norman, T.C., Gray, N.S., Koh, J.T. & Schultz, P.G. (1996). A structure-based approach to kinase inhibitors. J. Am. Chem. Soc. 118, 7430-7431.
14. Colas, P., Cohen, B., Jessen, T., Grishina, I., McCoy, J. & Brent, R. (1996). Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature 380, 548-550.
15. Penninger, J.M., Wallace, V.A., Kishihara, K. & Mak, T.W. (1993). The role of p56lck and p59fyn tyrosine kinases and CD45 protein tyrosine phosphatase in T-cell development and clonal selection. Immunol. Rev. 135, 183-214.
16. Ezumi, Y., Shindoh, K., Tsuji, M. & Takayama, H. (1998). Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets. J. Exp. Med. 188, 267-276.
17. Fox, J.E. (1996). Platelet activation: New aspects. Haemostasis 26 Suppl 4, 102-131.
18. Kawakami, Y., Yao, L., Miura, T., Tsukada, S., Witte, O.N. & Kawakami, T. (1994). Tyrosine phosphorylation and activation of bruton tyrosine kinase upon Fc epsilon RI cross-linking. Mol. Cell Biol. 14, 5108 5113.
19. Nishizumi, H., et al., & Yamamoto, T. (1995). Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity 3, 549-560.
20. Tsygankov, A.Y., Broker, B.M., Fargnoli, J., Ledbetter, J.A. & Bolen, J.B. (1992). Activation of tyrosine kinase p60fyn following T cell antigen receptor cross-linking. J. Biol. Chem. 267, 18259-18262.
21. Cooke, M.P., Abraham, K.M., Forbush, K.A. & Perlmutter, R.M. (1991). Regulation of T cell receptor signaling by a src family protein-tyrosine kinase (p59fyn). Cell 65, 281-291.
22. Levitski, A. (1996). SRC as a target for anti-cancer drugs. Anticancer Drug Des. 11, 175-182.
23. Showalter, H.D. & Kraker, A.J. (1997). Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and Src family tyrosine kinases. Pharmacol. Ther. 76, 55-71.
24. Hanke, J.H., et al., & Connelly, P.A. (1996). Discovery of a novel, potent, and src family-selective tyrosine kinase inhibitor. J. Biol. Chem. 271, 695-701.
25. Briddon, S.J. & Watson, S.P. (1999). Evidence for the involvement of p59fyn and p53/56lyn in collagen receptor signalling in human platelets. Biochem. J. 338, 203-209.
26. Amoui, M., Draber, P. & Draberova, L. (1997). Src family-selective tyrosine kinase inhibitor, PP1, inhibits both Fc epsilonri- and thy-1- mediated activation of rat basophilic leukemia cells. Eur. J. Immunol. 27, 1881-1886.
27. + exchangers. J. Biol. Chem. 274, 8093-8102.
28. Howlett, C.J., Bisson, S.A., Resek, M.E., Tigley, A.W. & Robbins, S.M. (1999). The proto-oncogene p120(Cbl) is a downstream substrate of the Hck protein-tyrosine kinase. Biochem. Biophys. Res. Commun. 257, 129-138.
29. Bishop, A.C., Moore, D., Scanlan, T.S. & Shokat, K.M. (1997). Screening a hydroxystilbene library for selective inhibition of the B cell antigen receptor kinase cascade. Tetrahedron 53, 11995-12004.
30. Siekierka, J.J. & Sigal, N.H. (1992). FK-506 and cyclosporin A: Immunosuppressive mechanism of action and beyond. Curr. Opin. Immunol. 4, 548-552.
31. Sigal, N.H. & Dumont, F.J. (1992). Cyclosporin A, FK-506, and rapamycin: Pharmacologic probes of lymphocyte signal transduction. Annu Rev. Immunol. 10, 519-560.
32. Zent, R., Ailenberg, M. & Silverman, M. (1998). Tyrosine kinase cell signaling pathways of rat mesangial cells in 3-dimensional cultures: Response to fetal bovine serum and platelet-derived growth factor-BB. Exp. Cell Res. 240, 134-143.
33. Frye, S.V. (1999). Structure-activity relationship homology (SARAH): A conceptual framework for drug discovery in the genomic era. Chem. Biol. 6, R3-R7.
34. Sicheri, F., Moarefi, I. & Kuriyan, J. (1997). Crystal structure of the src family tyrosine kinase hck. Nature 385, 602-609.
35. Garcia, P., Shoelson, S.E., George, S.T., Hinds, D.A., Goldberg, A.R. & Miller, W.T. (1993). Phosphorylation of synthetic peptides containing Tyr-Met-X-Met motifs by nonreceptor tyrosine kinases in vitro. J. Biol. Chem. 268, 25146-25151.
36. Xu, B., Bird, G.V. & Miller, T.W. (1995). Substrate specificities of the insulin and insulin-like growth factor 1 receptor tyrjosine kinase catalytic domains. J. Biol. Chem. 270, 29825-29830.
37. Liu, Y., Shah, K., Yang, F., Witucki, L. & Shokat, K.M. (1998). Engineering src family protein kinases with unnatural nucleotide specificity. Chem. Biol. 5, 91-101.
38. Wang, J.Y. & Baltimore, D. (1985). Localization of tyrosine kinase-coding region in v-abl oncogene by the expression of v-abl-encoded proteins in bacteria. J. Biol. Chem. 260, 64-71.
39. Colbran, R.J. (1992). Regulation and role of brain calcium/calmodulin-dependent protein kinase II. Neurochem. Int. 21, 469-497.
40. De Bondt, H.L., Rosenblatt, J., Jancarik, J., Jones, H.D., Morgan, D.O. & Kim, S.H. (1993). Crystal structure of cyclin-dependent kinase 2. Nature 363, 595-602.
41. Wilson, K.P., et al., & Su, M.S. (1997). The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 4, 423-431.
42. Eyers, P.A., Craxton, M., Morrice, N., Cohen, P. & Goedert, M. (1998). Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino acid substitution. Chem. Biol. 5, 321-328.
43. Fox, T., et al., & Wilson, K.P. (1998). A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase. Protein Sci. 7, 2249-2255.
44. Khokhlatchev, A., Xu, S., English, J., Wu, P., Schaefer, E. & Cobb, M.H. (1997). Reconstitution of mitogen-activated protein kinase phosphorylation cascades in bacteria. Efficient synthesis of active protein kinases. J. Biol. Chem. 272, 11057-11062.
45. Ruegg, U.T. & Burgess, G.M. (1989). Staurosporine, K-252 and UCN-01: Potent but nonspecific inhibitors of protein kinases. Trends Pharmacol. Sci. 10, 218-220.
46. Kang, T.B. & Liang, N.C. (1997). Effect of quercetin on activities of protein kinase C and tyrosine protein kinase from HL-60 cells. Chung Kuo Yao Li Hsueh Pao 18, 374-376.
47. Bishop, A.C. & Shokat, K.M. (1999). Acquisition of inhibitor-sensitive protein kinases through protein design. Pharmacol. Ther. 1-10.
48. Reikofski, J. & Tao, B.Y. (1992). Polymerase chain reaction (PCR) techniques for site-directed mutagenesis. Biotech. Adv. 10, 535-554.
49. Gray, N.S., et al., & Schultz, P.G. (1998). Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533-538.
50. Liu, Y., Shah, K., Yang, F., Witucki, L. & Shokat, K. (1998). Engineering src family protein kinases with unnatural nucleotide specificity. Chem. Biol. 5, 91-101.
51. Meijer, L. (1995). Chemical inhibitors of cyclin-dependent kinases. Prog. Cell Cycle Res. 1, 351-363.
52. Schindler T., Sicheri F., Pico A., Gazit A., Levitzki A., Kuriyan J. (1999). Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell 3, 639-648.
53. Zhu X, et al., & Morgenstern KA. (1999). Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure 7, 651-661.